Verona Pharma CEO: Ohtuvayre (Ensifentrine) Now Available in the U.S. for Maintenance Treatment of Chronic Obstructive Pulmonary Disease in Adults >VRNA
Verona Pharma CEO: Ohtuvayre (Ensifentrine) Now Available in the U.S. for Maintenance Treatment of Chronic Obstructive Pulmonary Disease in Adults >VRNA
維羅納製藥CEO：Ohtuvayre（Ensifentrine）現已在美國上市，用於治療成人慢性阻塞性肺病的維持治療>VRNA
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間